Answers are grounded in this paper and cite their sources.
The clinical outcomes of CCC are generally poorer than SC. Complete cytoreduction to no gross residual disease should be ideally achieved in CCC patients. A greater understanding of the molecular pathogenesis of CCC may lead to tailored therapies, ultimately optimizing outcomes.
No takes yet. Share an insight, caveat, or question.
Ku et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: